In today’s recent session, 0.47 million shares of the ATAI Life Sciences N.V (NASDAQ:ATAI) have been traded, and its beta is 1.18. Most recently the company’s share price was $1.31, and it changed around -$0.04 or -2.96% from the last close, which brings the market valuation of the company to $219.82M. ATAI at last check was trading at a discount to its 52-week high of $2.85, offering almost -117.56% off that amount. The share price’s 52-week low was $1.03, which indicates that the recent value has risen by an impressive 21.37% since then. We note from ATAI Life Sciences N.V’s average daily trading volume that its 10-day average is 1.36 million shares, with the 3-month average coming to 1.41 million.

ATAI Life Sciences N.V stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ATAI as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. ATAI Life Sciences N.V is expected to report earnings per share of -0.15 for the current quarter.

ATAI Life Sciences N.V (NASDAQ:ATAI) trade information

Instantly ATAI has been showing red trend so far today with a performance of -2.96% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.3800 on recent trading dayincreased the stock’s daily price by 5.07%. The company’s shares are currently down -7.09% year-to-date, but still up 9.17% over the last five days. On the other hand, ATAI Life Sciences N.V (NASDAQ:ATAI) is -26.40% down in the 30-day period. We can see from the shorts that 10.61 million shares have been sold at a short interest cover period of 5.49 day(s).

The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 78.17% from its current value. Analyst projections state that ATAI is forecast to be at a low of $6 and a high of $6.

ATAI Life Sciences N.V (ATAI) estimates and forecasts

ATAI Life Sciences N.V share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 0.77 percent over the past six months and at a -208.00% annual growth rate that is well below the industry average of 14.30%. The year-over-year growth rate is expected to be 159.03%, up from the previous year.

Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 250k in revenue for the current quarter. Analysts predict that the company’s current quarter sales will jump, forecast at 1,288.89%. Forecasts for the next quarter put sales growth at 0.00%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 44.19%.

ATAI Dividends

ATAI Life Sciences N.V’s next quarterly earnings report is expected to be released in January.

ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 9.99% of ATAI Life Sciences N.V shares, and 26.76% of them are in the hands of institutional investors. The stock currently has a share float of 29.73%. ATAI Life Sciences N.V stock is held by 104.0 institutions, with WALLEYE CAPITAL LLC being the largest institutional investor. By 2024-06-30, it held 1.7388% of the shares, which is about 2.76 million shares worth $3.67 million.

MORGAN STANLEY, with 1.7111% or 2.72 million shares worth $3.62 million as of 2024-06-30, holds the second largest percentage of outstanding shares.